<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02188589</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-NVC-13001</org_study_id>
    <nct_id>NCT02188589</nct_id>
  </id_info>
  <brief_title>Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse</brief_title>
  <official_title>Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirox, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirox, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and feasibility of the INEX Nasal Implant in subjects with moderate to
      severe nasal valve collapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Multi-Center, Non-Randomized, Prospective Exploratory Study of the INEX Nasal
      Implant. The purpose of this study is to evaluate the safety and feasibility of the INEX
      Nasal Implant in subjects with moderate to severe nasal valve collapse.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implant Related Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Implant related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Nasal patency assessed by validated NOSE (&quot;Nasal Obstruction Symptom Evaluation&quot;) Questionnaire. The NOSE score uses a 0 - 20 point scale to capture severity of breathing symptoms, with higher scores indicating more severe symptoms than lower scores. NOSE scores are converted to a 100-point scale by multiplying the total score by 5.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Nasal Valve Collapse</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bilateral or unilateral implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal implant</intervention_name>
    <description>Treatment group may receive bilateral nasal implants (maximum of 4, 2 per side)</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) The subject is ≥ 18 years of age. 2) The subject is willing and able to provide
             informed consent. 3) The subject is willing and able to comply with the study
             protocol. 4) The subject is seeking treatment for nasal obstruction on one or both
             sides of the nose and is willing to undergo an office-based or intraoperative nasal
             implant procedure in lieu of alternative treatments (i.e., surgical repair or use of
             an external dilator).

             5) The subject has a baseline NOSE Score ≥ 11. 6) The subject agrees to follow-up
             examinations for 18 months post treatment. 7) The investigator has determined that
             nasal valve collapse (NVC) is a primary or significant contributor to the subject's
             nasal obstruction based on clinical presentation, physical examination and nasal
             endoscopy.

             8) Patient agrees to have mupirocin ointment prior to implantation. 9) The subject has
             sufficient space available to receive the implant and the shape of the maxilla allows
             for an appropriate anchor location.

             10) The subject has been offered other available treatments and declined such
             treatments.

        Exclusion Criteria:

          -  1) The subject has had concomitant surgical or non-surgical treatment of their nasal
             valve or the subject has had prior rhinoplasty within 12 months.

             2) The subject has had septoplasty, inferior turbinate reduction or other surgical
             nasal procedures within the past six (6) months.

             3) The subject has had recurrent methicillin-resistant Staphylococcus aureas (MRSA)
             infections or has a current Staphylococcus infection.

             4) The subject plans to have concomitant surgical or non-surgical treatment of their
             nasal valve within 6 months of the study (through 6 month follow-up).

             5) The subject has used or plans to use intranasal steroids during treatment (within 2
             weeks pre-implant and 2 weeks post implantation).

             6) The subject has a permanent implant, dilator and/or uses an external device in the
             nasal area.

             7) The subject has concomitant inflammatory or infectious skin conditions or unhealed
             wounds in the treatment area.

             8) The subject has a cancerous or pre-cancerous lesion and/or has had radiation
             exposure in the treatment area or chemotherapy within 24 months of the study.

             9) The subject has known or suspected allergies or contraindications for any general
             or local anesthetic agents and / or any antibiotic medications.

             10) The subject has a history of significant bleeding disorders. 11) The subject is
             known or suspected to be pregnant or is lactating. 12) The subject has a known or
             suspected allergy to PLA or other bioresorbable materials.

             13) The subject has significant systemic disease such as chronic steroid use or poorly
             controlled diabetes which in the investigator's opinion could pre-dispose the subject
             to poor wound healing.

             14) The subject is currently using nasal oxygen or CPAP. 15) The subject is not a
             candidate for procedures conducted under general anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Berghaus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde am Klinikum der LMU</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Stewart MG, Witsell DL, Smith TL, Weaver EM, Yueh B, Hannley MT. Development and validation of the Nasal Obstruction Symptom Evaluation (NOSE) scale. Otolaryngol Head Neck Surg. 2004 Feb;130(2):157-63.</citation>
    <PMID>14990910</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <results_first_submitted>June 17, 2016</results_first_submitted>
  <results_first_submitted_qc>August 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2016</results_first_posted>
  <last_update_submitted>January 1, 2017</last_update_submitted>
  <last_update_submitted_qc>January 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Nasal implant: Treatment group may receive bilateral nasal implants (maximum of 4, 2 per side)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Nasal implant: Treatment group may receive bilateral nasal implants (maximum of 4, 2 per side)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Implant Related Adverse Events</title>
        <description>Implant related adverse events</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Nasal implant: Treatment group may receive bilateral nasal implants (maximum of 4, 2 per side)</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Related Adverse Events</title>
          <description>Implant related adverse events</description>
          <units>implant related adverse events</units>
          <param>Number</param>
          <units_analyzed>Number of Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Endpoint</title>
        <description>Nasal patency assessed by validated NOSE (&quot;Nasal Obstruction Symptom Evaluation&quot;) Questionnaire. The NOSE score uses a 0 - 20 point scale to capture severity of breathing symptoms, with higher scores indicating more severe symptoms than lower scores. NOSE scores are converted to a 100-point scale by multiplying the total score by 5.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Nasal implant: Treatment group may receive bilateral nasal implants (maximum of 4, 2 per side)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Endpoint</title>
          <description>Nasal patency assessed by validated NOSE (&quot;Nasal Obstruction Symptom Evaluation&quot;) Questionnaire. The NOSE score uses a 0 - 20 point scale to capture severity of breathing symptoms, with higher scores indicating more severe symptoms than lower scores. NOSE scores are converted to a 100-point scale by multiplying the total score by 5.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Nasal implant: Treatment group may receive bilateral nasal implants (maximum of 4, 2 per side)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nonsurgical implant retrieval</sub_title>
                <description>3/56 total implants placed were retrieved post implantation. Implant retrieval did not require surgical intervention and did not result in any adverse clinical sequelae.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>Includes reports of rhinitis and &quot;common cold&quot;, non-serious , not device related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>Non-serious, not device related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <description>Non-serious, not device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Non serious, not device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hypertension</sub_title>
                <description>Non-serious, not device-related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>A non-serious device related hematoma was observed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <description>A non-serious device related observation of inflammation was reported.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Injury by fallen tree</sub_title>
                <description>Non-serious, not device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Operating Officer</name_or_title>
      <organization>Spirox</organization>
      <phone>650-618-1440</phone>
      <email>mrosenthal@spiroxmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

